Effects of preventive migraine treatment with atogepant :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Efficacy of atogepant 60 mg in preventive migraine therapy

Migraine Migraine
Migraine Migraine

This study explored the impact of atogepant-based preventive care on overall well-being, everyday activities, and the burden of headaches across the migraine continuum.

See All

Key take away

Preventive therapy with atogepant 60 mg once daily effectively reduces migraine-related disability, improves daily performance, and enhances overall well-being.

Background

This study explored the impact of atogepant-based preventive care on overall well-being, everyday activities, and the burden of headaches across the migraine continuum.

Method

Using data from three 12-week randomized trials investigating a single daily dose of atogepant 60 mg for migraine prevention, patient-reported outcomes were analyzed. The ADVANCE trial included volunteers with low-frequency (4–8 monthly migraine days [MMDs]) and high-frequency (8–14 MMDs) episodic migraine. The PROGRESS trial focused on chronic migraine, while ELEVATE examined episodic migraine in individuals who had failed two to four classes of oral preventive therapies.

Result

Prophylactic treatment with atogepant markedly outperformed placebo across multiple measures. At week 12, improvements in Migraine-Specific Quality of Life (MSQoL) Role Function–Restrictive domain scores were observed, with least squares mean differences of 12.0 and 9.9 for low- and high-frequency episodic migraine in ADVANCE, 6.2 in PROGRESS, and 17.7 in ELEVATE.

Headache Impact Test-6 (HIT-6) scores also improved, with reductions of −4.7 and −3.4 in ADVANCE, −2.8 in PROGRESS, and −6.5 in ELEVATE. Activity Impairment in Migraine–Diary-Performance of Daily Activities scores exhibited similar benefits, with reductions of −2.3 and −4.5 in ADVANCE, −3.4 in PROGRESS, and −4.7 in ELEVATE.

Conclusion

Preventive use of atogepant 60 mg daily supported better migraine-related quality of life and functional improvements, regardless of headache frequency or past treatment failures.

Source:

Cephalalgia

Article:

Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials

Authors:

Christopher Gottschalk et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try:

loader